Latest News

PDMR Dealing

18 November 2020

London, New York, 18 November 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified...

Read more

Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease

11 November 2020

First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

- Potential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease

-Crohn’s Disease Therapeutics Market Size $4.7 Billion by 2025

Phase1b/2 clinical...

Read more

Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

02 November 2020

London/New York, 2 November 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces initiation of a collaborative clinical study investigating...

Read more

Demerger Update and timetable confirmation

29 October 2020

London, New York, 29 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the capital reduction required...

Read more

Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights

29 October 2020

London, New York, 29 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...

Read more

Issue of Equity on Exercise of Warrants

28 October 2020

London, New York, 28 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...

Read more

Page 1 of 22 Next